Our monthly roundup of ‘people on the move’ in Canada’s life science and biotech sectors.
Astellas Pharma announced that Nate Crisel has been promoted to vice president, Real World Informatics and Analytics (RWI). He will be reporting to chief financial officer, Chikashi Takeda.
Crisel will continue to be responsible for overseeing the RWI division, a central function accountable for expanding efficient, effective and compliant use of healthcare data across the entire Astellas value chain.
Prior to joining Astellas in 2008, Crisel served as an analytical chemist and pharmaceutical development project manager at Eli Lilly and Company. After Eli Lilly, he held roles ranging from business development and executive leadership at biotech start-ups, including Embedded Concepts, LLC, and Tracera, LLC.
Crisel received a Master of Business Administration in finance and entrepreneurship from Purdue University’s Krannert School of Management and a Bachelor of Science in chemistry from Indiana University.
MedChart has appointed Dennis Giokas as its Chief Information Officer. Dennis was most recently chief technology officer for Canada Health Infoway and led the organization’s Digital Health Innovation Ecosystem Group.
He has more than three decades of experience in the information management and technology fields and has held positions at Sapient Corporation as vice-president and managing director of its Canadian subsidiary. He has held senior positions with Digital Equipment Corporation and consulted on information technology strategy in other industries including financial services, insurance, and energy services.
Dennis is on the Ontario Institute for Cancer Research Board. He also advises clients through his consulting company Theoria Health Innovations Inc. and has served as a board director of COACH, Canada’s health informatics association, and HL7 International Inc. He is the past chair and Canada’s representative to the SNOMED International General Assembly and holds two patents for software innovations. He graduated from Boston University with a M.Sc. in computer science.
Deborah Brown, managing partner of specialist consultancy firm Accelera Canada has been named to the board of directors of Oncolytics Biotech Inc.
Oncolytics is developing Reolysin, an intravenously delivered immuno-oncolytic virus that is a potential treatment for a variety of tumour types.
As managing partner of Accelera Canada, Brown is involved in helping emerging biopharma ventures in the United States and Europe with the development and implementation of Canadian market strategies.
Brown held progressively senior roles at EMD Serono from 2000 to 2014, including executive vice-president of neuroimmunology for the company’s U.S. operations, and president and managing director of the company’s Canadian operations.
In 2012, she was Chair of the National Pharmaceutical Organization (now Innovative Medicines Canada) and served on its board of directors from 2007 to 2014.
Brown sits on the Boards of Life Sciences Ontario, the Strategic Executive Advisory Council for Canadian Cancer Trials Group, and her local SPCA. She holds an MBA from University of Western Ontario’s Ivey School of Business, an Hons B.Sc. from the University of Guelph and completed the Merck executive development program at the University of Hong Kong, INSEAD and Northwestern University’s Kellogg School of Management.
Doctors Manitoba has selected Theresa Oswald as its new Chief Executive Officer. Theresa was the province’s first female Minister of Health and now becomes Doctors Manitoba’s first female CEO. She will take over from Robert Cram, who is retiring after 22 years with Doctors Manitoba including 15 years as director of negotiations and the last seven years as CEO.
Her tenures in politics were as an NDP MLA from 2003 to 2016, a cabinet minister from 2004 until 2014 and minister of health from 2006 to 2013. Recently, she was the executive director of the Women’s Health Clinic in Winnipeg.
National Access Cannabis Corp., announced that Dr. Tyler Wish has joined the company to establish and lead its research and development division. In this executive role, Wish will be responsible for furthering the company’s efforts to advance knowledge of medicinal cannabis as a pharmaceutical product and to enhance its efficacy and safety across multiple patient populations.
He is a trained clinical and molecular epidemiologist, as well as an accomplished entrepreneur and life-science executive who was recently recognized and appointed as 1 of 10 “Canadian Innovation Leaders” by the Federal Minister of Innovation, Science and Economic Development. Prior to joining NAC, Tyler was a founder and the chief executive officer of Sequence Bio, a privately-held biotechnology company that leads a large-scale human genome sequencing initiative designed to support genetic-driven drug discovery and precision medicine.
Fountain Asset Corp. announced that Roger Daher has been appointed as a member of the board of directors at Fountain.
Roger Daher has an extensive background in the pharmacy industry with over 30 years of experience. He is currently an independent director on several boards including GreenSpace Brands Inc. and Xylitol Canada Inc. as well as a practicing owner and partner in seven Ontario Pharmasave pharmacies. Roger obtained his Bachelor of Science from the University of Toronto in 1989.
Invictus MD Strategies Corp. has announced the appointment of Dylan Easterbrook as chief financial officer.
Easterbrook is a seasoned accounting and financial professional, who most recently was the controller of a publicly traded global fibre optic connectivity solution provider. Prior to that role, he was with Ernst & Young, one of the largest professional services firms in the world where he led audit engagements for both public and privately held companies from a variety of industries, including the emerging markets.
Dylan is a Canadian Chartered Professional Accountant and holds a Bachelor of Science in Life Sciences degree from the University of British Columbia.
“We are excited about Dylan’s appointment as he brings solid experience and capabilities that match our needs as we continue to develop,” said Dan Kriznic, chairman & CEO, of Invictus MD. “The timing is ideal as we continue to execute on an aggressive development strategy aimed at creating Canada’s Cannabis Company.”
Northern Biologics announces that Philip Vickers, PhD, will be joining the company as CEO and a member of the board. Former CEO and founder, Stefan Larson, PhD, will remain on the board.
Vickers is a distinguished R&D leader with more than two decades of experience in the biotech and pharmaceutical industry. Most recently, he served as global head of R&D and a member of the executive committee for Shire during a period of substantial growth and multiple regulatory approvals for the company. By the time Philip left the company, he had grown the clinical development pipeline to approximately 40 programs.
Prior to joining Shire, he held a range of R&D positions in Big Pharma at Merck & Co. Inc., Pfizer Inc., Boehringer Ingelheim and Resolvyx Pharmaceuticals Inc. He received his Ph.D. in biochemistry from the University of Toronto.
The government of Ontario has appointed Molly Shoichet to be the Chief Scientist of Ontario. She will advise the premier, Kathleen Wynne, directly on scientific matters to demonstrate Ontario’s ongoing commitment to grow the economy by advancing science and innovation in the province. Molly is a professor at the University of Toronto and a member of the Order of Ontario. She will report to Reza Moridi, Minister of Research, Innovation and Science.
Shoichet studied at the Massachusetts Institute of Technology and received her bachelor’s degree in chemistry in 1987. She attended doctoral studies and earned her PhD in polymer science and engineering in 1992 at the University of Massachusetts Amherst. After receiving her doctorate, she joined the faculty of Brown University as an adjunct professor, while continuing to work in the industry. Shoichet joined the University of Toronto in 1995. Her work includes tissue and polymer engineering, with a focus on drug delivery and tissue regeneration.
Nuvo Pharmaceutical promotes Jesse Ledger internally, adding the role of chief executive officer to his current title of president. Jesse assumes this role from John London, who is now the executive chairman of the Mississauga based company.
Ledger has over 15 years of pharmaceutical experience with a proven expertise in business development. Prior to joining Nuvo in April of 2015, he was vice-president of business development and international Business at Tribute Pharmaceuticals Canada. Ledger holds an honours bachelor of business administration degree from Trent University.
Alzheimer’s might be a whole-body problem Next Post:
Study from U of G identifies key protein in cancer metastasis